Is TELO diluting shareholders?

Read three numbers together: shares outstanding over time (68.8M as of 2026-05-14), warrants that can convert into new shares, and how much cash runway remains (~2.4542881219720902 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Telomir Pharmaceuticals, Inc. (TELO)

CIK 1971532 · all EDGAR filings →

Overall dilution risk

HIGHworst of 3 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

not every sub-rating was computable; treat as a floor

Offering ability

HIGHS-3 on file 2025-02-14

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

NOT COMPUTEDno warrant count tagged in XBRL

= warrant shares outstanding divided by current shares outstanding

absence of a tag is not proof of absence of warrants

Historical dilution

HIGH+132% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

HIGH~2.5 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 68.8M shares as of May 14, 2026 (10-Q).

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

Tranche	Warrants	Exercise price	Term	Notes
Bay Shore Trust Warrants	2.4M	not tagged	2.2y	—
Two Thousand Twenty Three Private Placement Warrants	335,032	not tagged	—	—

Tranches exactly as the company dimensioned them in its 10-Q filed May 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.

Convertible notes

No convertible-note facts tagged in the 10-Q filed May 14, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	68.8M	May 14, 2026
+ Bay Shore Trust Warrants (if exercised)	2.4M	Mar 31, 2026
+ Two Thousand Twenty Three Private Placement Warrants (if exercised)	335,032	Mar 31, 2026
Fully diluted estimate	71.5M	+4.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Feb 14, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

S-1Nov 14, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 0 registered.

EXECUTEDApr 24, 2026Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDMay 21, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →

EFFECTIVEFeb 28, 2025SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDFeb 14, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →

EXECUTEDDec 11, 2024Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDFeb 12, 2024Prospectus supplement priced — shares or notes (large filers: often a bond deal)424B1 →

EXECUTEDFeb 12, 2024Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

EFFECTIVEFeb 8, 2024SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDJan 3, 2024S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

REGISTEREDDec 19, 2023S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

REGISTEREDDec 14, 2023S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full TELO workspace